HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Levosimendan, a new inotropic drug: experience in children with acute heart failure].

AbstractINTRODUCTION:
Low cardiac output syndrome occurs frequently in pediatric patients after cardiac surgery. Catecholamines are used as inotropic drugs to treat this threatening condition, but may cause undesirable and potentially harmful side effects. This study was performed to evaluate the efficacy and safety of levosimendan (LEVO) in pediatric patients with low cardiac output syndrome.
PATIENTS AND METHODS:
Open prospective, quasi-experimental cohort. LEVO was given as compassionate treatment in patients with refractory post-surgical low cardiac output syndrome. Every patient received an IV infusion of LEVO at 6 microg/kg during a fifteen minutes period, followed by a 24 h IV infusion at 0.1 microg/kg/min. Clinical improvement of cardiac output was the primary end point of the study. Two independent observers performed clinical evaluation, bidimensional echocardiogram, hemodynamic and laboratory tests were performed pre and after LEVO infusion.
RESULTS:
LEVO was infused in 18 opportunities (fourteen children). The response was considered successful in 9/18 interventions (50%; p= 0.004). Both inotropic score (12.1 vs. 6,1, p= 0.01) and A-VDO(2)2 (26.78 +/- 11.5% vs. 20.81 +/- 7.72%, p= 0.029) showed reduction, while SvO2 improved (69.5 +/- 11.4% vs. 76 +/- 9.29%, p= 0.03). No adverse effects were noticed. Four patients died, none of them related to LEVO administration.
CONCLUSIONS:
LEVO improved cardiac output in 50% of the interventions with post-surgical LCOS and no adverse effect was observed.
AuthorsRicardo Magliola, Guillermo Moreno, Juan C Vassallo, Luis M Landry, María Althabe, María Balestrini, Alberto Charroqui, Gladys Salgado, Evangelina Lataza, Anthony C Chang
JournalArchivos argentinos de pediatria (Arch Argent Pediatr) Vol. 107 Issue 2 Pg. 139-45 (Apr 2009) ISSN: 1668-3501 [Electronic] Argentina
Vernacular TitleLevosimendán, un nuevo agente inotrópico: experiencia en niños con fallo cardíaco agudo.
PMID19452086 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Simendan
Topics
  • Acute Disease
  • Adolescent
  • Cardiac Output, Low (drug therapy)
  • Cardiotonic Agents (therapeutic use)
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Hydrazones (therapeutic use)
  • Infant
  • Male
  • Prospective Studies
  • Pyridazines (therapeutic use)
  • Simendan

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: